Enhancement of atherosclerosis in Beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice

Pathobiology

Volumn 67, Issue 1, 1999, Pages 19-25

  Afek, Arnon ^a   George, Jacob ^a   Shoenfeld, Yehuda ^a,b   Gilburd, Boris ^a   Levy, Yair ^a   Shaish, Aviv ^a   Keren, Pnina ^a   Janackovic, Zora ^a   Goldberg, Iris ^a   Kopolovic, Juri ^a   Harats, Dror ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

2 glycoprotein I; Anticardiolipin antibodies; Apolipoprotein E deficient mice; Atherosclerosis; Low density lipoprotein, oxidized

Indexed keywords

APOLIPOPROTEIN E; BETA2 GLYCOPROTEIN 1; CHOLESTEROL; OVALBUMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; HYPERLIPOPROTEINEMIA TYPE 3; IMMUNIZATION; LIPID DIET; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; BETA 2-GLYCOPROTEIN I; DIETARY FATS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNIZATION; LDL-RECEPTOR RELATED PROTEIN 1; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OVALBUMIN; RECEPTORS, LIPOPROTEIN; RISK FACTORS;

ANIMALIA;

EID: 6544275289     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028046     Document Type: Article

References (42)

1. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362: 801-809.
2. Libby P, Hansson GK: Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions. Lab Invest 1991;64:5-15.
3. Wick G, Schett G, Amberger A, Kleindienst R, Xu Y: Is atherosclerosis an immunologically mediated disease? Immunol Today 1995;16: 27.
4. George J, Harats D, Gilburd B, Shoenfeld Y: Emerging crossregulatory roles of immunity and autoimmunity in atherosclerosis. Immunol Res 1996;155:315-322.
5. Tsakraklidesm VG, Blieden IC, Edwards JE: Coronary atherosclerosis and myocardial infarction associated with systemic lupus erythemotosus. Am Heart J 1974;87:637.
6. Josson H, Nived O, Sturfelt G: Outcome of systemic lupus erythematosus: A prospective study of patients from a defined population. Medicine (Baltimore) 1989;68:141.
7. Hughes GRV: The antiphospholipid syndrome: Ten years on. Lancet 1993;342:341.
8. Hojnik M, George J, Ziporen L, Shoenfeld Y: Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996;93:1579.
9. Harris EN: Annonation. Antiphospholipid antibodies. Br J Haematol 1990;74:1.
10. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA: Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β2GPI (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120.
11. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB: 'Anticardiolipin' autoantibodies recognize beta-2-glycoprotein in the absence of phospholipid. Importance of antigen density and bivalent binding. J Immunol 1995;154: 954-960.
12. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T, Yasuda T, Koike T: Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 1992;148:3885.
13. Ferro D, Pittoni V, Quintarelli C, Basili S, Saliola M, Caroselli C, Velesini G, Violi F: Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Circulation 1997;95:1425-1432.
14. Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch DW, Palinski W, Witztum JL: Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest 1996;98:815-825.
15. Valesini G, Shoenfeld Y: A new player in the antiphospholipid syndrome. The beta 2 glycoprotein I cofactor. Autoimmunity 1992;14: 105.
16. Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S, Koike T: Antibodies to β2GPI and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:1466.
17. Cabrai AR, Cabiedes J, Alarcon-Segovia D: Antibodies to phospholipid-free beta-2-glycoprotein I in patients with primary antiphospholipid syndrome. J Rheumatol 1995;24: 1894-1898.
18. Gharavi AE, Sammaritano LR, Wen J, Elkon KB: Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest 1992; 90:1105.
19. Pierangeli SS, Harris EN: Induction of phospholipid binding antibodies in mice and rabbits by immunization with human beta 2 glycoprotein 1 of anticardiolipin antibodies alone. Clin Exp Immunol 1993;93:269.
20. Kouts S, Wang MX, Adelstein S, Krilis SA: Immunization of a rabbit with beta 2 glycoprotein I induces charge dependent cross-reactive antibodies that bind phospholipids and have similar reactivity as autoimmune antiphospholipid antibodies. J Immunol 1995;155:958.
21. Blank M, Faden D, Tincani A, Kopolovic J, Goldber I, Gilburd B, Allegri F, Balestrieri G, Valesini G, Shoenfeld Y: Immunization with anticardiolipin cofactor (beta 2 glycoprotein I) induces antiphospholipid syndrome in naive mice. J Autoimmun 1994;7:441.
22. Garcia C, Kanbour-Shakir A, Tang H, Espinoza LR, Gharavi AE: Induction of experimental antiphospholipid syndrome in PL/J mice following immunization with beta 2 glycoprotein I. J Invest Med 1996;44:69a.
23. Aron AL, Cuellar RL, Brey RL, Meceown S, Espinoza LR, Shoenfeld Y, Gharavi AE: Early onset of autoimmunity in mr1/++ mice following immunization with beta 2 glycoprotein I. Clin Exp Immunol 1995;101:78.
24. George J, Afek A, Gilburd B, Blank M, Levy Y, et al: Induction of early atherosclerosis in LDL receptor deficient mice immunized with β2GPI. Circulation 1998;15:1108.
25. George J, Afek A, Gilburd B, Levy Y, Blank M, Kopolovic Y, Haratz D, Shoenfeld Y: Atherosclerosis in LDL receptor knockout mice is accelerated by immunization with anticardiolipin antibodies. Lupus 1997;6:723-729.
26. Plump AS, Smith JD, Hayek T, Aalto Setala K, Walsh A. Verstuyft JG, Rubine EM, Breslow JL: Severe hypercholesterolemia and atherosclerosis in apolipoprotein-E deficient mice created by homologous recombination in ES cells. Cell 1992;71:343.
27. Zhang SH, Reddick RL, Piedrahita JA, Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein. Science 1992;258:468.
28. George J, Blank M, Hojnik M, Bar-Meir E, Koike T, Matsuura E, Lorber M, Aviram M, Shoenfeld Y: Oxidized low density lipoprotein (ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome. Clin Exp Immunol 1997;108:227.
29. Matsuura E, Katahira T, Igarashi M, Koike T: Beta 2 glycoprotein I bind to oxidatively modified lipoproteins could be targeted by anticardiolipin antibodies. Lupus 1994;3:314.
30. Xu Q, Dietrich H, Steiner HJ, Gown AM, Schoel B, Mikuz G, Kaufman SHE, Wick G: Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 1992; 12:789.
31. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Paliniski W, Witztum JL: Antibodies against oxidized LDL and the progression of carotid atherosclerosis. Lancet 1992;339:883.
32. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA: Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 1987;68:231.
33. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM: Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature 1991;353:265.
34. Esterbaur H, Striegel G, Puhl H, Rotheneder M: Continuous monitoring of in-vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989;6:67-75.
35. Palinski W, Miller E, Witztum JL: Immunization of low density lipoprotein (LDL) deficient rabbits with homologous malondialdehydemodified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995;92:821-825.
36. Ameli SA, Hultgardh-Nilsson A, Regenstrom J, Calara F. Yana J, Cercek B, Shah PK, Nilsson J: Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996;16:1074-1079.
37. George J, Afek A, Gilburd B, Levkovitch H, Shaish A, Goldberg I, Kopolovic J, Shoenfeld Y, Harats D: Hyperimmunization of chow-fed ApoE deficient mice with homologous oxidized low density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998;138:147.
38. Gupta S, Pablo AM, Jiang XC, Wang N, Tall AR. Schindler C: INF-γ potentiates atherosclerosis in ApoE knockout mice. J Clin Invest 1997;99:2752.
39. Roselaar SE, Kakkanthu PX, Daugherty A: Lymphocyte population in atherosclerosis lesions of ApoE -/- and LPL receptor -/- mice. Decreasing density with disease progression. Arterioscler Thromb Vasc Biol 1996;16:1013-1018.
40. Zhou X, Stemme S, Hansson GK: Evidence for a local immune response in atherosclerosis. CD+ T cells infiltrate lesions of apoprotein-E mice. Am J Pathol 1996;149:359.
41. George J, Blank M, Levy Y, Meroni PL, Damianovitch M, Tincani A, Shoenfeld Y: Differential effects of anti-β2 glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 1998;97:900-906.
42. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T: Involvement of β2 glycoprotein I and anticardiolipin antibodies in oxidatively modified LDL uptake by microphages. Clin Exp Immunol 1997;197:569.